Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

SVB Leerink starts VectivBio at OP; PT $28

SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...

May 4, 2021

Markets

WB cuts Lucira Heath to market perform

William Blair downgraded Lucira Health (NASDAQ:LHDX) to “market perform,” citing changes to the testing market that have played out over the last couple of months coupled with lack of demand for the company’s at-home...

May 4, 2021

Markets

Stifel starts ProQR Therapeutics at buy; PT $20

Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...

May 3, 2021

Markets

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...

May 3, 2021

Markets

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...

May 3, 2021

Markets

BTIG starts DermTech at buy; PT $53

BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...

May 3, 2021

Markets

HCW starts Sio Gene Therapies at buy; PT $8

H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...

April 30, 2021

Markets

Raymond James ups Cardiol Therapeutics to OP from MP

Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...

April 28, 2021

Markets

HCW starts Akouos at buy; PT $25

H.C. Wainwright launched coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $25 price target. The stock closed at $15.03 on April 26. Akouos is a precision genetic medicine company focused primarily on the...

April 27, 2021

Markets

Stifel ups Xenon Pharma PT to $31 from $23

Stifel raised its price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $31 from $23, ahead of Phase 2b focal seizure data expected in the third quarter this year. The stock closed at $17.97 on April 23. “From our...

April 26, 2021

Markets

HCW starts Adicet Bio at buy; PT $27

H.C. Wainwright launched coverage of Adicet Bio (NASDAQ:ACET) with a “buy” rating and $27 price target. The stock closed at $13.11 on April 22. Adicet is focused on developing allogeneic gamma-delta T-cell therapies for...

April 23, 2021

Markets

Maxim starts CohBar at buy; PT $3

Maxim Group initiated coverage of CohBar (NASDAQ:CXBR), which is developing a therapeutic platform based on mitochondrial-derived peptides, with a “buy” rating and price target of $3. The stock closed at $1.24 on April...

April 23, 2021

Markets

Maxim ups Cerecor to buy from hold; PT $7

Maxim Group upgraded Cerecor (NASDAQ:CERC) to “buy” from “hold” with a price target of $7, citing an advancing pipeline of assets and the potential for multiple priority review vouchers (PRVs). The stock closed at $2.34...

April 21, 2021

Markets

Cantor starts 89bio at OW; PT $58

Cantor Fitzgerald launched coverage of 89bio (NASDAQ:ETNB) with an “overweight” rating and $58 price target. The stock closed at $25.81 on April 20. 89bio is developing BIO89-100, its injectable FGF21 hormone analog...

April 21, 2021

Markets

Maxim starts Fennec Pharma at buy: PT $12

Maxim Group initiated coverage of Fennec Pharmaceuticals (NASDAQ:FENC) with a “buy” rating and price target of $12. The stock closed at $6.27 on April 16. Fennec is developing PEDMARK, a unique formulation of sodium...

April 19, 2021

Markets

Echelon starts Cognetivity Neurosciences at speculative buy; PT 85 cents (Canadian)

Echelon Capital Markets initiated coverage of Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF)) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 48.5 cents on April 16...

April 19, 2021

Markets

SVB Leerink starts Lava Therapeutics at OP; PT $26

SVB Leerink launched coverage of Lava Therapeutics N.V. (NASDAQ:LVTX) with an “outperform” rating and $26 price target. The stock closed at $15 on April 16. Lava is at the leading edge of therapeutically targeting the...

April 19, 2021

Markets

Citi transfers coverage of 111 Inc. with $16 PT

Citi Research transferred coverage of 111 Inc. (NASDAQ:YI) to Zoe Bian from Cui Cui, retaining a “buy/high risk” rating and price target of $16. Citi recently raised its price target to $16 from $12. The stock closed at...

April 19, 2021

Markets

BTIG ups TRACON Pharma to buy from neutral with $14 PT

BTIG upgraded TRACON Pharmaceuticals (NASDAQ:TCON) to “buy” from “neutral” with a new price target of $14, citing pivotal trial dosing for the company’s envafolimab and expansion opportunities, which are under...

April 16, 2021

Markets

Canaccord starts Exagen at buy; PT $25

Canaccord Genuity launched coverage of Exagen (NASDAQ:XGN) with a “buy” rating and $25 price target. The stock closed at $16.69 on April 14. Analyst Max Masucci writes that Exagen provides a broad range of tests used to...

April 15, 2021

Markets

SVB Leerink starts Connect Biopharma at OP; PT $32

SVB Leerink launched coverage of Connect Biopharma Holdings (NASDAQ:CNTB) with an “outperform” rating and price target of $32. The stock closed at $17.05 on April 12. Connect is a clinical-stage biotech headquartered in...

April 13, 2021

Markets

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

April 12, 2021

Subscribe